AHR and cancer: Increased IDO expression and accumulation of kynurenine can deplete tryptophan, impair effector T and NK cell responses, favor regulatory immune populations and activate Aryl Hydrocarbon Receptor (AHR)-dependent oncogenic signaling, thereby promoting cancer cell survival and proliferation [9,10].